SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : ARIAD Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: jaybe who wrote (4271)5/19/2016 12:06:49 AM
From: Biomaven  Read Replies (2) | Respond to of 4474
 
>>but if 75% of patients in Arm B have not experienced progression at 11.1 months

But they claim 11.1 months is the median. So I'm still confused. Could that be the median of people that have progressed? If so that would of course be fantastic, but very strange way to report things.



To: jaybe who wrote (4271)5/19/2016 11:36:37 AM
From: Biomaven1 Recommendation

Recommended By
glass 0.5 full

  Read Replies (1) | Respond to of 4474
 
>>Also helpful to note FDA labels for both alectinib and ceritinib show 44% ORR as determined by IRC

Have to do an apples to apples comparison though - IRC rates are consistently lower than investigator rates.

Peter


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News